Welcome to our dedicated page for Amylyx Pharmaceuticals SEC filings (Ticker: AMLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Amylyx Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Amylyx Pharmaceuticals's regulatory disclosures and financial reporting.
Amylyx Pharmaceuticals Chief Legal Officer receives new equity awards. On March 5, 2026, Gina Mazzariello was granted stock options for 111,990 shares at an exercise price of $0.00 per share and an award of 74,660 shares of common stock in the form of restricted stock units.
The RSU award vests in four equal annual installments starting March 1, 2027, contingent on continued service. The stock option vests with 25% on March 1, 2027 and the remainder monthly over the next 36 months, also subject to continued service. Following these awards, she directly holds 209,090 shares of common stock.
Amylyx Pharmaceuticals Chief Financial Officer James M. Frates reported equity compensation awards in the form of stock options and restricted stock units. On March 5, 2026, he was granted stock options for 143,985 shares at an exercise price of $0.00 per share, and a separate grant of 95,990 shares of common stock as a restricted stock unit award.
The RSUs vest in four equal annual installments starting on March 1, 2027, subject to his continued service. Twenty‑five percent of the option vests on March 1, 2027, with the remainder vesting monthly over the following 36 months, also subject to continued service. Additional common shares are held indirectly by various family trusts for which he serves as trustee, and he disclaims beneficial ownership of those shares except to the extent of any pecuniary interest.
Amylyx Pharmaceuticals Co-Chief Executive Officer Justin B. Klee reported equity awards from the company. He received a stock option for 373,295 shares at an exercise price of $0.0000 per share and a grant of 248,865 shares of common stock as restricted stock units (RSUs).
The RSUs vest in four equal annual installments starting on March 1, 2027, conditioned on his continued service. The option vests 25% on March 1, 2027, with the remaining shares vesting monthly over the next 36 months, also subject to continued service. After these grants, he reported owning 3,583,481 shares of common stock directly.
Amylyx Pharmaceuticals granted Chief Medical Officer Camille L. Bedrosian equity awards on March 5, 2026. She received stock options for 143,985 shares at an exercise price of $0.00 and 95,990 shares of common stock as a restricted stock unit award.
The RSUs vest in four equal annual installments starting on March 1, 2027, subject to continued service. Twenty-five percent of the option vests on March 1, 2027, with the remainder vesting monthly over the following 36 months, also contingent on ongoing service.
Amylyx Pharmaceuticals Co-Chief Executive Officer Justin B. Klee reported an open-market sale of common stock tied to tax withholding. On March 2, he sold 29,282 shares at a weighted average price of $14.4717 per share to cover withholding obligations from vesting restricted stock units. The filing notes these sales were automatic and not at his discretion, and he continued to hold 3,334,616 shares of Amylyx common stock directly after the transaction.
Amylyx Pharmaceuticals director and Co-CEO Joshua B. Cohen reported an automatic tax-related share sale. On March 2, 2026, 29,282 shares of common stock were sold at a weighted average price of $14.484 per share to cover tax withholding owed on vesting restricted stock units.
The filing notes these sales were required to satisfy withholding obligations and were not made at Cohen’s discretion. After the transaction, he continues to directly own 3,334,683 shares of Amylyx common stock, indicating he retains a substantial equity stake in the company.
Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian reported an automatic sale of 6,461 shares of common stock on March 2, 2026 to cover tax withholding obligations arising from the vesting of restricted stock units. The shares were sold at a weighted average price of $14.5806 per share in multiple trades between $14.440 and $14.945. After these tax-related sales, Bedrosian held 169,295 shares of Amylyx common stock directly.
Amylyx Pharmaceuticals Chief Financial Officer James M. Frates reported an automatic share sale related to tax withholding. On March 2, 2026, he sold 7,909 shares of common stock in an open-market transaction at a weighted average price of $14.5216 per share to cover taxes from restricted stock unit vesting.
After this sale, he directly held 165,638 shares. The filing also notes indirect holdings through several trusts, including 100,000 shares, 15,459 shares and 11,072 shares, where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
Amylyx Pharmaceuticals Chief Legal Officer Gina Mazzariello reported an automatic sale of 6,844 shares of common stock on March 2, 2026 to cover tax withholding from vesting restricted stock units. The weighted average sale price was $14.5205 per share, and she held 134,430 shares afterward.
Amylyx Pharmaceuticals, Inc. filed an automatic shelf registration on March 3, 2026 to register an offering program for common stock, preferred stock, debt securities, warrants and units to be sold from time to time.
The prospectus states Amylyx is a well-known seasoned issuer using Form S-3ASR and may sell securities on a continuous or delayed basis; specific terms will be provided in prospectus supplements. The company’s common stock trades on Nasdaq under the symbol AMLX, with a closing sale price of $15.30 on March 2, 2026.